Definium Therapeutics Inc. Announces Inducement Grants for New Employees

The inducement grants consist of options to purchase a total of 169,740 common shares of the company, known as "Options." The effective grant date of these options aligns with the company’s efforts to incentivize its new hires, ensuring their alignment with Definium's long-term goals. The exercise price for these options is set to match the closing price of Definium’s common shares on the date of the grants, providing a fair and transparent compensation structure for the employees.

The Options are structured to vest over a four-year period, with a quarter of the options becoming available on the first anniversary of the grant date. The remaining 75% will vest in equal monthly increments over the subsequent three years, contingent upon each employee's continued employment. This vesting schedule not only encourages employee retention but also aligns the interests of the new hires with those of the company’s shareholders.

The issuance of these inducement grants was approved by Definium's Compensation Committee on June 25, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. By adhering to these regulatory guidelines, Definium demonstrates its commitment to corporate governance and transparency in its compensation practices.

Founded with a mission to revolutionize psychiatry, Definium Therapeutics is dedicated to developing innovative therapeutics that target the underlying causes of psychiatric and neurological disorders. The company is focused on applying scientific rigor to the field of psychedelics, aiming to create accessible treatments that can significantly improve mental health outcomes for patients.

Definium's approach is rooted in the belief that patients deserve more than just incremental improvements in their treatment options. By investing in a new generation of therapeutics, the company seeks to change the trajectory of the ongoing mental health care crisis and foster a healthier future for individuals suffering from various mental health conditions.

Headquartered in New York, Definium Therapeutics is publicly traded on Nasdaq under the symbol DFTX. The company's innovative strategies and commitment to mental health care position it as a key player within the biopharmaceutical landscape, particularly in the realm of psychiatric and neurological treatments.

As Definium Therapeutics continues to grow and expand its team, the recent inducement grants are a clear indication of the company's proactive approach to attracting skilled professionals who share its vision of transforming mental health care. With a focus on evidence-based treatments and a dedication to making therapeutic advancements accessible, Definium stands poised for a promising future in the industry.